Assembly Biosciences Total Assets 2010-2024 | ASMB

Assembly Biosciences total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Assembly Biosciences Annual Total Assets
(Millions of US $)
2023 $137
2022 $102
2021 $191
2020 $283
2019 $340
2018 $268
2017 $169
2016 $98
2015 $134
2014 $71
2013 $27
2012 $21
2011 $37
2010 $15
2009 $0
Assembly Biosciences Quarterly Total Assets
(Millions of US $)
2024-06-30 $115
2024-03-31 $120
2023-12-31 $137
2023-09-30 $52
2023-06-30 $67
2023-03-31 $83
2022-12-31 $102
2022-09-30 $122
2022-06-30 $143
2022-03-31 $163
2021-12-31 $191
2021-09-30 $249
2021-06-30 $262
2021-03-31 $279
2020-12-31 $283
2020-09-30 $306
2020-06-30 $295
2020-03-31 $313
2019-12-31 $340
2019-09-30 $223
2019-06-30 $242
2019-03-31 $259
2018-12-31 $268
2018-09-30 $283
2018-06-30 $142
2018-03-31 $156
2017-12-31 $169
2017-09-30 $112
2017-06-30 $123
2017-03-31 $134
2016-12-31 $98
2016-09-30 $109
2016-06-30 $117
2016-03-31 $124
2015-12-31 $134
2015-09-30 $140
2015-06-30 $145
2015-03-31 $138
2014-12-31 $71
2014-09-30 $60
2014-06-30 $22
2014-03-31 $24
2013-12-31 $27
2013-09-30 $32
2013-06-30 $34
2013-03-31 $37
2012-12-31 $21
2012-09-30 $24
2012-06-30 $29
2012-03-31 $31
2011-12-31 $37
2011-09-30 $53
2011-06-30 $12
2011-03-31 $14
2010-12-31 $15
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.107B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00